Bliss GVS Pharma Limited (BLISSGVS.NS)
INR 169.0
(0.87%)
INR 169.0
(0.87%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.7 Billion INR | 2.48% |
| 2022 | 7.51 Billion INR | 1.85% |
| 2021 | 7.37 Billion INR | 29.76% |
| 2020 | 5.68 Billion INR | -16.6% |
| 2019 | 6.81 Billion INR | -23.04% |
| 2018 | 8.86 Billion INR | 143.55% |
| 2017 | 3.63 Billion INR | -54.51% |
| 2016 | 7.99 Billion INR | 46.23% |
| 2015 | 5.46 Billion INR | 34.33% |
| 2014 | 4.07 Billion INR | 17.37% |
| 2013 | 3.46 Billion INR | -12.55% |
| 2012 | 3.96 Billion INR | 48.73% |
| 2011 | 2.66 Billion INR | 21.86% |
| 2010 | 2.18 Billion INR | 29.59% |
| 2009 | 1.68 Billion INR | 27.02% |
| 2008 | 1.32 Billion INR | 29.84% |
| 2007 | 1.02 Billion INR | 64.26% |
| 2006 | 623.39 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.83 Billion INR | -7.31% |
| 2024 Q2 | 2.17 Billion INR | 18.53% |
| 2023 Q3 | 2 Billion INR | -5.27% |
| 2023 Q1 | 1.59 Billion INR | -13.67% |
| 2023 FY | 7.7 Billion INR | 2.48% |
| 2023 Q4 | 1.98 Billion INR | -1.29% |
| 2023 Q2 | 2.11 Billion INR | 32.82% |
| 2022 Q2 | 1.72 Billion INR | -8.6% |
| 2022 Q4 | 1.84 Billion INR | -10.18% |
| 2022 FY | 7.51 Billion INR | 1.85% |
| 2022 Q1 | 1.88 Billion INR | 19.76% |
| 2022 Q3 | 2.05 Billion INR | 19.3% |
| 2021 Q4 | 1.57 Billion INR | -27.15% |
| 2021 Q1 | 1.68 Billion INR | 36.11% |
| 2021 FY | 7.37 Billion INR | 29.76% |
| 2021 Q2 | 1.95 Billion INR | 16.56% |
| 2021 Q3 | 2.16 Billion INR | 10.34% |
| 2020 Q2 | 1.51 Billion INR | 16.97% |
| 2020 Q1 | 1.29 Billion INR | 15.25% |
| 2020 FY | 5.68 Billion INR | -16.6% |
| 2020 Q4 | 1.23 Billion INR | -24.7% |
| 2020 Q3 | 1.64 Billion INR | 8.26% |
| 2019 Q4 | 1.12 Billion INR | -23.97% |
| 2019 Q1 | 2.11 Billion INR | -8.79% |
| 2019 Q2 | 2.1 Billion INR | -0.67% |
| 2019 Q3 | 1.47 Billion INR | -29.64% |
| 2019 FY | 6.81 Billion INR | -23.04% |
| 2018 FY | 8.86 Billion INR | 143.55% |
| 2018 Q3 | 2.2 Billion INR | -3.5% |
| 2018 Q4 | 2.31 Billion INR | 5.21% |
| 2018 Q2 | 2.28 Billion INR | 12.89% |
| 2018 Q1 | 2.02 Billion INR | 20.97% |
| 2017 Q4 | 1.67 Billion INR | -14.61% |
| 2017 FY | 3.63 Billion INR | -54.51% |
| 2017 Q2 | 2.26 Billion INR | 0.48% |
| 2017 Q1 | 2.25 Billion INR | -12.81% |
| 2017 Q3 | 1.95 Billion INR | -13.43% |
| 2016 Q1 | 1.4 Billion INR | -2.38% |
| 2016 FY | 7.99 Billion INR | 46.23% |
| 2016 Q4 | 2.58 Billion INR | 11.24% |
| 2016 Q3 | 2.32 Billion INR | 37.31% |
| 2016 Q2 | 1.69 Billion INR | 20.66% |
| 2015 Q2 | 1.76 Billion INR | 85.57% |
| 2015 FY | 5.46 Billion INR | 34.33% |
| 2015 Q4 | 1.43 Billion INR | 8.44% |
| 2015 Q3 | 1.32 Billion INR | -24.81% |
| 2015 Q1 | 948.81 Million INR | 0.0% |
| 2014 FY | 4.07 Billion INR | 17.37% |
| 2013 FY | 3.46 Billion INR | -12.55% |
| 2012 Q4 | 1.48 Billion INR | 82.8% |
| 2012 FY | 3.96 Billion INR | 48.73% |
| 2012 Q1 | 637.41 Million INR | 0.0% |
| 2012 Q2 | 1.02 Billion INR | 61.47% |
| 2012 Q3 | 813.16 Million INR | -20.99% |
| 2011 FY | 2.66 Billion INR | 21.86% |
| 2010 FY | 2.18 Billion INR | 29.59% |
| 2009 FY | 1.68 Billion INR | 27.02% |
| 2008 FY | 1.32 Billion INR | 29.84% |
| 2007 FY | 1.02 Billion INR | 64.26% |
| 2006 FY | 623.39 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sigachi Industries Limited | 3.98 Billion INR | -93.065% |
| Ind-Swift Limited | 5.02 Billion INR | -53.292% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -62.699% |
| Sakar Healthcare Limited | 1.54 Billion INR | -399.616% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 97.344% |
| Innova Captab Limited | 10.81 Billion INR | 28.767% |
| Divi's Laboratories Limited | 78.45 Billion INR | 90.182% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 40.546% |
| Morepen Laboratories Limited | 17.01 Billion INR | 54.742% |
| Mankind Pharma Limited | 103.34 Billion INR | 92.547% |
| Sequent Scientific Limited | 13.69 Billion INR | 43.767% |
| Wanbury Limited | 5.75 Billion INR | -33.804% |
| Laurus Labs Limited | 50.01 Billion INR | 84.601% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 54.276% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 66.265% |
| Alembic Limited | 1.57 Billion INR | -389.09% |
| Hikal Limited | 17.84 Billion INR | 56.839% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 87.398% |
| Neuland Laboratories Limited | 15.58 Billion INR | 50.58% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 77.659% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 93.48% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 63.886% |
| Themis Medicare Limited | 3.81 Billion INR | -101.761% |
| RPG Life Sciences Limited | 5.82 Billion INR | -32.333% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 95.951% |
| Lupin Limited | 196.56 Billion INR | 96.081% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -82.856% |
| Wockhardt Limited | 27.89 Billion INR | 72.383% |
| Vaishali Pharma Limited | 862.79 Million INR | -792.73% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 57.574% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -269.064% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 88.509% |
| FDC Limited | 19.42 Billion INR | 60.357% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.241% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -398.952% |
| Eris Lifesciences Limited | 20.09 Billion INR | 61.663% |
| Venus Remedies Limited | 5.91 Billion INR | -30.23% |
| ZIM Laboratories Limited | 3.67 Billion INR | -109.581% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -705.355% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 54.064% |
| Shilpa Medicare Limited | 11.53 Billion INR | 33.203% |
| Albert David Limited | 3.62 Billion INR | -112.504% |
| Ajanta Pharma Limited | 42.08 Billion INR | 81.699% |
| Hester Biosciences Limited | 3.04 Billion INR | -152.916% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 26.738% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 37.803% |
| Gufic Biosciences Limited | 8.06 Billion INR | 4.515% |
| Windlas Biotech Limited | 6.3 Billion INR | -22.076% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 33.095% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | -94.694% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -109.674% |
| Granules India Limited | 45.06 Billion INR | 82.908% |
| Aarti Drugs Limited | 25.28 Billion INR | 69.538% |
| Bal Pharma Limited | 3.39 Billion INR | -127.064% |
| Alkem Laboratories Limited | 126.67 Billion INR | 93.92% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.412% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | -32.675% |
| Medicamen Biotech Limited | 1.79 Billion INR | -329.57% |
| Unichem Laboratories Limited | 16.57 Billion INR | 53.527% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -405.192% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1823.914% |
| Valiant Laboratories Limited | 1.82 Billion INR | -323.079% |
| Orchid Pharma Limited | 8.19 Billion INR | 5.995% |
| Medico Remedies Limited | 1.44 Billion INR | -431.494% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 39.867% |
| Ipca Laboratories Limited | 77.05 Billion INR | 90.004% |
| Brooks Laboratories Limited | 794.86 Million INR | -869.031% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -197.112% |
| Piramal Enterprises Limited | 60.33 Billion INR | 87.234% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 92.737% |
| NATCO Pharma Limited | 40.02 Billion INR | 80.754% |
| Suven Life Sciences Limited | 116.92 Million INR | -6487.287% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1427.612% |
| Strides Pharma Science Limited | 40.51 Billion INR | 80.987% |
| Indoco Remedies Limited | 18.17 Billion INR | 57.616% |
| Alpa Laboratories Limited | 1.08 Billion INR | -608.343% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -638.242% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -919.58% |